COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03210753
Recruitment Status : Unknown
Verified May 2017 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : July 7, 2017
Last Update Posted : July 13, 2017
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:

Background and objective

The introduction of a proteasome inhibitor bortezomib has significantly improved response rates and overall survival in patients with multiple myeloma (MM), and it has soon become the cornerstone of treatment in both newly diagnosed and relapsed/refractory settings. However, the incidence of peripheral neuropathy related to bortezomib (BiPN) is unignorable and which becomes an obstacle during treatment with bortezomib, either alone or in combination. Until now, there are no consistent findings regarding the risk factors that may cause BiPN. There is either lack of large scale study of BiPN in Taiwan. This study aims to clarify risk factors of BiPN using retrospective analysis in a large cohort with longer observation period as well as the relations between BiPN and gene polymorphisms, and to compare different routes in the incidence of BiPN.


This is a retrospective cohort study with a sample size of about 400 MM patients treated ever with at least one full cycle of bortezomib in the institution. All the patients enrolled need to be adults (≧20 years ) with measurable M-component in either blood or urine. The investigators will perform a retrospective chart review to collect clinical data, including anti-MM and concomitant medications, to evaluate the incidence and severity of BiPN in this cohort, as well as any meaningful risk factors contributed to BiPN. The investigators also plan to perform genotyping for the possible genetic factors associated with development of BiPN.

Expected contributions

The successful collaboration between clinical hematologist-oncologist and biopharmaceutical researcher would result in the concrete evidence of efficacy and safety of bortezomib in Taiwanese patients with MM. The findings in this large cohort study will unveil the risk factors of BiPN, including the administration routes and ethnicity. As results, the investigators would be able to provide the precision medicine-based bortezomib treatment strategy to MM patients in Taiwan.

Condition or disease
Multiple Myeloma

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma
Actual Study Start Date : December 1, 2016
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2020

Primary Outcome Measures :
  1. peripheral neuropathy [ Time Frame: 2006/4/1-2016/12/31 ]
    identified the record of peripheral neuropathy, neuropathy, numbness, tingling, weakness symptoms by chart review

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The population from a medical center in Taiwan

Inclusion criteria

  1. Age >20 years
  2. Diagnosed with MM
  3. Bortezomib new users (2006/4/1-2016/6/30)

Exclusion criteria

  1. Varying on IV and SC administration
  2. Receive bortezomib at other hospitals

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03210753

Layout table for location contacts
Contact: Chou Jia-Shan 0952389250

Layout table for location information
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Huang Shang-Yi    02-23123456 ext 63575   
Sponsors and Collaborators
National Taiwan University Hospital
Layout table for investigator information
Principal Investigator: Huang Shang-Yi National Taiwan University Hospital
Layout table for additonal information
Responsible Party: National Taiwan University Hospital Identifier: NCT03210753    
Other Study ID Numbers: 201610048RINA
First Posted: July 7, 2017    Key Record Dates
Last Update Posted: July 13, 2017
Last Verified: May 2017
Keywords provided by National Taiwan University Hospital:
Multiple Myeloma
Peripheral neuropathy
Subcutaneous injection
Risk factors
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Peripheral Nervous System Diseases
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Neuromuscular Diseases
Nervous System Diseases